<DOC>
	<DOCNO>NCT00772889</DOCNO>
	<brief_summary>The purpose observer-blind clinical trial evaluate safety immunogenicity GlaxoSmithKline Biologicals ' influenza vaccine GSK2186877A elderly . Subjects previously vaccinate ( NCT00529516 ) .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity Influenza Vaccine GSK2186877A Elderly</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female subject previously enrol study 109821 ( NCT 00529516 ) &gt; = 65 year 1841 year age group receive study vaccine . Subjects investigator believe comply requirement protocol . Specific attention give compliance potential subject suspect known drug alcohol abuse . Written inform consent obtain subject . Free acute aggravation health status establish medical history clinical examination enter study If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 30 day vaccination . Planned administration influenza vaccine study vaccine entire study period . Any vaccination influenza since January 2008 seasonal influenza vaccine . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History hypersensitivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination preexist laboratory screening test . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan administration study period . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day prior vaccination , plan use study period . Any medical condition intramuscular injection contraindicate . Pregnant lactating female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>